Nintedanib
![Nintedanib Structure](CAS/GIF/656247-17-5.gif)
- CAS No.
- 656247-17-5
- Chemical Name:
- Nintedanib
- Synonyms
- Intedanib;Nintedanib (BIBF 1120);INTEDANIB BASE;methyl (3Z)-3-{[(4-{methyl[(4-methylpiperazin-1-yl)acetyl]amino}phenyl)amino](phenyl)methylidene;(3Z)-3-[[4-[methyl-[2-(4-methylpiperazin-1-yl)acetyl]amino]anilino]-phenylmethylidene]-2-oxo-1H-indole-6-carboxylate;methyl (3Z)-2-hydroxy-3-[({4-[N-methyl-2-(4-methylpiperazin-1-yl)acetamido]phenyl}amino)(phenyl)methylidene]-3H-indole-6-carboxylate;100837;Nidanib;NTEDANIB;Vargatef
- CBNumber:
- CB72510401
- Molecular Formula:
- C31H33N5O4
- Molecular Weight:
- 539.64
- MOL File:
- 656247-17-5.mol
- Modify Date:
- 2024/4/18 12:02:32
Melting point | >237oC (dec.) |
---|---|
Boiling point | 742.2±60.0 °C(Predicted) |
Density | 1.284±0.06 g/cm3(Predicted) |
storage temp. | Refrigerator |
solubility | DMSO (Slightly), Methanol (Slightly) |
form | Yellow solid. |
pka | 11.06±0.20(Predicted) |
color | Light Yellow to Light Green |
InChIKey | XZXHXSATPCNXJR-ZIADKAODSA-N |
SMILES | C(/C1C=CC=CC=1)(=C1\C(NC2=CC(C(=O)OC)=CC=C\12)=O)\NC1C=CC(N(C)C(=O)CN2CCN(C)CC2)=CC=1 |
SAFETY
Risk and Safety Statements
Symbol(GHS) | ![]() GHS07 |
|||||||||
---|---|---|---|---|---|---|---|---|---|---|
Signal word | Warning | |||||||||
Hazard statements | H302-H315-H319-H335 | |||||||||
Precautionary statements | P261-P264-P270-P271-P280-P301+P312-P302+P352-P304+P340-P305+P351+P338-P330-P332+P313-P337+P313-P362-P403+P233-P405-P501 | |||||||||
NFPA 704 |
|
Nintedanib Chemical Properties,Uses,Production
Definition
ChEBI: A member of the class of oxindoles that is a kinase inhibitor used (in the form of its ethylsulfonate salt) for the treatment of idiopathic pulmonary fibrosis and cancer.
Side effects
The most common side effects of Nintedanib in clinical studies were gastrointestinal-related side effects, including nausea (31%), vomiting (23%), diarrhoea (76%), abdominal pain (10%) and decreased appetite (10%). Other side effects were hepatic impairment commonly seen as elevated liver enzymes, weight loss (7 per cent), nasopharyngitis (7 per cent), cough (14 per cent), upper respiratory tract infections (14 per cent), headache (12 per cent), fatigue (14 per cent), skin ulcers (16 per cent) and urinary tract infections (12 per cent).
Reported post-marketing adverse events include gastrointestinal perforation, proteinuria and pancreatitis. In several clinical trials, nidanib has also been found to be associated with an increased risk of bleeding, possibly secondary to VEGFR inhibition. Although serious bleeding and arterial thromboembolic events (e.g., myocardial infarction (MI) and stroke) are rare, bleeding events with serious and fatal consequences have been reported in post-marketing surveillance. Therefore, the use of nidazanib has been associated with an increased risk of bleeding, possibly secondary to VEGFR inhibition. Therefore, patients treated with nidazanib and receiving full anticoagulation therapy need to be closely monitored for adverse bleeding events.
Nintedanib Preparation Products And Raw materials
Raw materials
1of2
chevron_rightPreparation Products
Supplier | Tel | Country | ProdList | Advantage | Inquiry |
---|---|---|---|---|---|
HEMA PHARMACEUTICALS PVT LTD | +91-9537936912 +91-9537936912 | Gujarat, India | 48 | 58 | Inquiry |
Metrochem API Private Limited | +91-4069069999 +91-4069069999 | Telangana, India | 78 | 58 | Inquiry |
Glenmark Pharmaceuticals Limited | +912240189999 | Maharashtra, India | 93 | 58 | Inquiry |
Apex Healthcare Limited | +9199825711244 | Gujarat, India | 22 | 58 | Inquiry |
Sai Life Sciences Ltd | +91-4066777555 +91-8008555365 | Hyderabad, India | 24 | 58 | Inquiry |
Shilpa Medicare Limited (SML) | +91-8532238704 +91-9320649838 | Karnataka, India | 61 | 58 | Inquiry |
MSN LABORATORIES PRIVATE LTD | +91 40 30438600 | New Delhi, India | 230 | 58 | Inquiry |
A.J Chemicals | 91-9810153283 | New Delhi, India | 6124 | 58 | Inquiry |
CLEARSYNTH LABS LTD. | +91-22-45045900 | Hyderabad, India | 6351 | 58 | Inquiry |
SynZeal Research Pvt Ltd | +1 226-802-2078 | Gujarat, India | 6522 | 58 | Inquiry |
Related articles
- Nintedanib: Uses, Mechanism of Action and Side Effects
- Nintedanib is a small molecule tyrosine kinase inhibitor (TKI) that binds to a family of growth factor receptors and blocks th....
- Apr 18,2024
656247-17-5(Nintedanib)Related Search:
1of4
chevron_right